IRIS UniCatt

Cassano, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.455
EU - Europa 4.125
AS - Asia 3.648
SA - Sud America 651
AF - Africa 117
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.007
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.310
SG - Singapore 1.754
DE - Germania 1.483
CN - Cina 723
SE - Svezia 636
BR - Brasile 527
IT - Italia 439
VN - Vietnam 417
PL - Polonia 326
FR - Francia 291
GB - Regno Unito 229
IN - India 176
IE - Irlanda 143
UA - Ucraina 142
FI - Finlandia 120
ID - Indonesia 104
JP - Giappone 83
RU - Federazione Russa 78
HK - Hong Kong 75
CA - Canada 70
TR - Turchia 60
BD - Bangladesh 53
MX - Messico 50
AR - Argentina 48
BE - Belgio 41
CI - Costa d'Avorio 37
IQ - Iraq 37
ZA - Sudafrica 36
AT - Austria 32
NL - Olanda 31
ES - Italia 29
IR - Iran 25
EC - Ecuador 21
CZ - Repubblica Ceca 17
LT - Lituania 17
PK - Pakistan 17
SA - Arabia Saudita 17
KR - Corea 14
MA - Marocco 13
CO - Colombia 12
UZ - Uzbekistan 12
VE - Venezuela 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
CL - Cile 11
PY - Paraguay 10
RO - Romania 9
LU - Lussemburgo 8
PH - Filippine 8
NP - Nepal 7
PT - Portogallo 7
AZ - Azerbaigian 6
IL - Israele 6
OM - Oman 6
PE - Perù 6
AL - Albania 5
AU - Australia 5
BG - Bulgaria 5
JO - Giordania 5
KE - Kenya 5
LV - Lettonia 5
MD - Moldavia 5
TT - Trinidad e Tobago 5
CR - Costa Rica 4
EG - Egitto 4
LB - Libano 4
NO - Norvegia 4
SN - Senegal 4
TN - Tunisia 4
BO - Bolivia 3
ET - Etiopia 3
EU - Europa 3
GE - Georgia 3
JM - Giamaica 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LK - Sri Lanka 3
RS - Serbia 3
SV - El Salvador 3
AO - Angola 2
CG - Congo 2
CM - Camerun 2
DK - Danimarca 2
HN - Honduras 2
HU - Ungheria 2
IS - Islanda 2
KW - Kuwait 2
ML - Mali 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
QA - Qatar 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AW - Aruba 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
Totale 13.994
Salva come PNG Salva come JPEG
Città #
Singapore 1.028
Chandler 795
Ashburn 502
San Jose 454
Warsaw 307
Fairfield 171
New York 165
Beijing 155
Dublin 141
Ho Chi Minh City 127
Los Angeles 126
Wilmington 125
San Mateo 120
Ann Arbor 116
Hanoi 104
Jacksonville 97
Houston 93
Lauterbourg 93
Nürnberg 91
Woodbridge 91
Jakarta 88
Nanjing 83
Seattle 76
Council Bluffs 75
Tokyo 74
Boston 73
Chicago 73
Rome 70
Frankfurt am Main 68
Cattolica 66
Hong Kong 66
Dallas 63
Munich 63
Helsinki 62
Cambridge 58
Princeton 57
Milan 56
The Dalles 53
Dearborn 52
São Paulo 50
Redmond 48
Hyderabad 47
Moscow 45
Hefei 42
London 42
Marseille 41
Brussels 40
Santa Clara 40
Abidjan 37
Izmir 36
Nanchang 32
Orem 32
Boardman 28
Denver 28
Redwood City 28
Shanghai 28
Bremen 26
Lawrence 25
Matera 24
Paris 24
Brooklyn 23
Buffalo 23
Falls Church 23
Montreal 21
Augusta 20
Toronto 20
Johannesburg 19
Leawood 19
Norwalk 19
Nuremberg 19
Mountain View 18
Rio de Janeiro 18
Vienna 18
Poplar 17
Amsterdam 16
Haiphong 16
Phoenix 16
Chennai 15
Düsseldorf 15
Hebei 15
Hangzhou 14
Kraków 14
Lancaster 14
Lappeenranta 14
Manchester 14
San Francisco 14
Stockholm 14
Dong Ket 13
Mumbai 13
Changsha 12
Da Nang 12
Guangzhou 12
Kent 12
Kish 12
Mexico City 12
Tianjin 12
Turku 12
Atlanta 11
Belo Horizonte 11
Brasília 11
Totale 7.543
Salva come PNG Salva come JPEG
Nome #
Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival 408
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy 351
Pembrolizumab as first-line treatment for metastatic uveal melanoma 344
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real- world experience 338
C-myc expression is a possible keystone in the colorectal cancer resistance to egfr inhibitors 320
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? 307
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 252
Complete Metabolic Response with Recanalization of Portal Vein Tumor Thrombosis after Sunitinib in a Patient with Advanced Hepatocellular Carcinoma 236
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients 234
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis 227
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 227
[Gastrointestinal stromal tumors] 208
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. 208
Thymoma in patients with MG: characteristics and long-term outcome 198
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo 194
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases 190
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 184
Gastrointestinal stromal tumors (GISTs) and second malignancies A novel sentinel tumor? A monoinstitutional, STROBE-compliant observational analysis 182
Trastuzumab-induced corneal ulceration: successful no-drug treatment of a "blind" side effect in a case report 182
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients 181
PDGFRA-mutant syndrome 181
Standardizing percutaneous Microwave Ablation in the treatment of Lung Tumors: a prospective multicenter trial (MALT study) 176
Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive 172
“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome 171
Liver metastasectomy for metastatic breast cancer patients: A single institution retrospective analysis 163
KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study 160
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases 158
HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 158
Are TKIs favourable for the elderly with non-small-cell lung cancer? 155
Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. 154
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 152
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity 148
Transradial versus Transfemoral Access for Hepatic Chemoembolization: Intrapatient Prospective Single-Center Study 146
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 146
ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas 145
Let‐7a‐5p, mir‐100‐5p, mir‐101‐3p, and mir‐199a‐3p hyperexpression as potential predictive biomarkers in early breast cancer patients 145
Palbociclib plus fulvestrant or everolimus plus exemestane for pretreated advanced breast cancer with lobular histotype in er+/her2− patients: A propensity score-matched analysis of a multicenter retrospective patient series 143
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 140
RUNX3 as a Potential Predictor of Metastasis in Human Pancreatic Cancer 140
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation 140
Advanced colon cancer: staging and prognosis by CEA test 137
Interventional oncology treatment for unresecable early stage HCC in patient with high risk for intraprocedural bleeding: is a single step combined therapy safe and feasible? 137
Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. 136
[Gastrointestinal stromal tumors] 135
First-line treatment of advanced biliary ducts carcinoma: A randomized phase II study evaluating 5-FU/LV Plus oxaliplatin (Folfox 4) versus 5-FU/LV (de gramont regimen) 134
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: A single institution phase II study 132
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 131
Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents 130
Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium 130
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer 129
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. 128
Neoadjuvant chemotherapy for patients with muscle-invasive urothelial bladder cancer candidates for curative surgery: A prospective clinical trial based on cisplatin feasibility 126
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX 125
From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer? 125
Immunological backbone of uveal melanoma: Is there a rationale for immunotherapy? 125
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer 125
Divergent gastrointestinal stromal tumors in syndromic settings 123
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. 123
Clinical outcomes of teeth adjacent to the site of mandibulotomy or mandibulectomy in patients with head and neck cancer: results from a multidisciplinary mono-institutional head and neck tumor board 122
eComment. Iterative metastasectomy for recurrent pulmonary disease from colorectal cancer: A challenging issue 121
Successful "on- demand" plerixafor for autologous peripheral blood stem-cells transplantation for relapsed/refractory germ cell tumors. 121
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives 117
Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity. 116
Novel epigenetic eight-gene signature predictive of poor prognosis and msi-like phenotype in human metastatic colorectal carcinomas 116
Osteoradionecrosis incidence in pre‐radiation teeth extractions: A prospective study 115
In reply to the letter to the editor regarding "Clinical outcomes of teeth adjacent to the site of mandibulotomy or mandibulectomy in patients with head and neck cancer: results from a multidisciplinary mono-institutional head and neck tumor board" 115
Targeted Therapy in Advanced Gastric Carcinoma:the Future is Beginning 112
Operator learning curve for transradial liver cancer embolization: Implications for the initiation of a transradial access program 112
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 108
Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? 106
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 104
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 104
Authors' reply “Osteoradionecrosis incidence in preradiation teeth extractions: A prospective study” 103
Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? 103
Oral Health Status in Patients with Head and Neck Cancer before Radiotherapy: Baseline Description of an Observational Prospective Study 101
Percutaneous radiofrequency ablation using internally cooled wet electrodes for the treatment of patients with lung tumors 100
Long term follow up of a pilot study with neoadjuvant EEP ( epidoxorubicin, Etoposide and Cisplatin) in gastric cancer. 99
Primary cardiac synovial sarcoma: A review correlating outcomes with surgery and adjuvant therapy 99
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 98
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer 97
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 97
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 95
Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer 93
Cryoablation in Locoregional Management of Complex Unresectable Chest Neoplasms 92
Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more? 90
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 87
Treatment of locally advanced gastric cancer (LAGC): Back to lauren’s classification in pan– cancer analysis era? 86
Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study 84
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse 82
Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. 80
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 75
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study) 74
Targeted therapy in advanced gastric carcinoma: The future is beginning 73
Triple positive breast cancer: A distinct subtype? 67
Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study 66
Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors 61
Lung adenocarcinoma presenting as a solitary gingival metastasis: a case report 60
Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line 46
Totale 14.192
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.354
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.354
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021132 0 0 0 0 0 0 0 0 0 0 105 27
2021/2022973 79 45 21 111 60 40 22 149 52 59 132 203
2022/20232.031 272 285 158 348 110 240 98 192 197 38 66 27
2023/2024794 32 223 31 32 30 121 54 39 13 32 86 101
2024/20251.802 37 65 139 98 152 66 48 100 237 223 330 307
2025/20265.005 685 132 275 685 989 290 965 244 373 286 81 0
Totale 14.192